Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been assigned an average rating of “Moderate Buy” from the twenty-six analysts that are currently covering the stock, MarketBeat.com reports. Ten investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $793.7391.

REGN has been the subject of several recent analyst reports. Canaccord Genuity Group lowered their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Benchmark upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research report on Tuesday, July 7th. Cantor Fitzgerald increased their target price on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $803.48 on Tuesday. Regeneron Pharmaceuticals has a 12-month low of $541.00 and a 12-month high of $821.11. The firm has a market capitalization of $82.73 billion, a price-to-earnings ratio of 19.86, a price-to-earnings-growth ratio of 1.37 and a beta of 0.22. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The firm has a fifty day moving average of $675.79 and a 200-day moving average of $714.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $12.81 EPS. On average, equities research analysts forecast that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be given a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This trade represents a 31.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $320,000.00. Following the completion of the sale, the director owned 603 shares in the company, valued at approximately $482,400. This trade represents a 39.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,400 shares of company stock valued at $1,090,030. Company insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of REGN. BlackRock Inc. acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $5,682,636,000. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $1,012,296,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Regeneron Pharmaceuticals by 142.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after purchasing an additional 1,144,887 shares during the last quarter. Nuveen LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after purchasing an additional 835,240 shares in the last quarter. Finally, Legal & General Group Plc bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $473,872,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron is expanding its oncology relationship with Biohaven through a clinical supply agreement to test Biohaven’s BHV-1530 alongside Regeneron’s Libtayo in patients with solid tumors. The combination could strengthen Regeneron’s oncology pipeline if clinical results are favorable. Biohaven-Regeneron Oncology Deal
• Positive Sentiment: Regeneron also entered a strategic research collaboration with Parabilis Medicines to develop antibody-Helicon conjugates. The agreement includes $125 million in upfront consideration and equity investment for Parabilis, with potential milestone payments of up to $2.2 billion plus royalties—highlighting Regeneron’s efforts to broaden its technology base and future pipeline. Parabilis Medicines-Regeneron Collaboration
• Neutral Sentiment: Coverage highlights Regeneron’s exposure to GLP-1-related growth opportunities beyond the leading weight-loss drug makers, although the article provides limited new company-specific financial information. GLP-1 Demand and Regeneron
• Neutral Sentiment: Director Kathryn Guarini sold $320,000 of REGN stock under a pre-arranged Rule 10b5-1 trading plan. Because the sale was scheduled in advance, it is a limited indicator of management’s current outlook.
• Negative Sentiment: Multiple law firms are promoting a securities class action against Regeneron concerning alleged disclosures about the Phase 3 fianlimab-Libtayo melanoma trial. The trial’s failure reportedly erased approximately $11 billion in market value, and the continuing legal notices may keep investor attention focused on potential litigation costs, disclosure risks and weakness in the oncology program. The lead-plaintiff deadline is September 14, 2026. Regeneron Class Action Lawsuit

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.